Author

S. Kint

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

K. Vandereyken· 2 shared T. Voet· 2 shared A. Antoranz· 1 shared A. Ly· 1 shared A. Nowosad· 1 shared A. Sifrim· 1 shared B. De Moor· 1 shared C. Y. Mah· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

K. Vandereyken

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Integration of Multiple Spatial-Omics Modalities Reveals Unique Insights into Molecular Heterogeneity of Prostate Cancer

W. Zhang, X. Spotbeen, S. Vanuytven, S. Kint, T. Sarretto, F. Socciarelli, K. Vandereyken, J. Dehairs, J. Idkowiak, D. Wouters, J. I. Alvira Larizgoitia, G. Partel, A. Ly, V. de Laat, M. J. Q. Mantas, , J. V. Swinnen

This paper integrates multiple spatial-omics modalities in prostate cancer samples to reveal molecular heterogeneity and correlations between lipids and gene expression.

bioRxiv · Aug 28, 2023 · PreprintCancer Biology

A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanoma

J. Pozniak, D. Pedri, E. Landeloos, Y. Van Herck, A. Antoranz, P. Karras, A. Nowosad, S. Makhzami, G. Bervoets, M. Dewaele, L. Vanwynsberghe, S. Cinque, S. Kint, K. Vandereyken, T. Voet, , J.-C. Marine

This study identifies a TCF4/BRD4-dependent regulatory network that drives cross-resistance to ICB and targeted therapy in melanoma by analyzing scRNA-seq data from a longitudinal cohort.

bioRxiv · Aug 11, 2022 · PreprintCancer Biology